Prostate specific antigen detected prostate cancer (clinical stage T1c): An interim analysis

Journal of Urology

Volumn 155, Issue 3, 1996, Pages 821-826

  Lerner, Seth E ^a,b   Seay, Thomas M ^a   Blute, Michael L ^a   Bergstralh, Erik J ^a   Barrett, David ^a   Zincke, Horst ^a  

^a MAYO CLINIC   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

antigens; neoplasm; prostate specific antigen; prostatectomy; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TUMOR DIFFERENTIATION;

EID: 0030034351     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66317-1     Document Type: Article

References (28)

1. Boring, C. C., Squires, T. S., Tong, T. and Montgomery, S.: Cancer statistics, 1994. CA, 44: 7, 1994.
2. Mettlin, C., Jones, G., Averette, H., Gusberg, S. B. and Murphy, G. P.: Defining and updating the American Cancer Society guidelines for cancer-related checkup: prostate and endometrial cancers. CA, 43: 42, 1993.
3. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A. and Andriole, G. E.: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl. J. Med., 324: 1156, 1991.
4. Brawer, M. K., Chetner, M. P., Beatie, J., Buchner, D. M., Vessella, R. L. and Lange, P. H.: Screening for prostatic carcinoma with prostate specific antigen. J. Urol., part 2, 147: 841, 1992.
5. Guthman, D. A., Wilson, T. M., Blute, M. L., Bergstralh, E. J., Zincke, H. and Oesterling, J. E.: Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics. Urology, 42: 150, 1993.
6. Stamey, T. A., Kabalin, J. N., McNeal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol., 141: 1076, 1989.
7. Partin, A. W., Carter, H. B., Chan, D. W., Epstein, J. I., Oesterling, J. E., Rock, R. C., Weber, J. P. and Walsh, P. C.: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 143: 747, 1990.
8. Blackwell, K. L., Bostwick, D. G., Myers, R. P., Zincke, H. and Oesterling, J. E.: Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J. Urol., 151: 1565, 1994.
9. Oesterling, J. E., Suman, V. J., Zincke, H. and Bostwick, D. G.: PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol. Clin. N. Amer., 20: 687, 1993.
10. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J.A.M.A., 271: 368, 1994.
11. Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907, 1991.
12. Utz, D. C. and Farrow, G. M.: Pathologic differentiation and prognosis of prostatic carcinoma. J.A.M.A., 209: 1701, 1969.
13. Bostwick, D. G., Myers, R. P. and Oesterling, J. E.: Staging of prostate cancer. Sem. Surg. Oncol., 10: 60, 1994.
14. Zincke, H., Blute, M. L., Fallen, M. J. and Farrow, G. M.: Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J. Urol., 146: 1053, 1991.
15. Winkler, H. Z., Rainwater, L. M., Myers, R. P., Farrow, G. M., Therneau, T. M., Zincke, H. and Leiber, M. M.: Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin. Proc., 63: 103, 1988.
16. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J. Amer. Stat. Ass., 53: 457, 1958.
17. Cox, D. R.: Regression models and life-tables. J. Roy. Stat. Soc., 34: 187, 1972.
18. Adolfsson, J. and Tribukait, B.: Evaluation of tumor progression by repeated fine needle biopsies in prostate adenocarcinoma: modal deoxyribonucleic acid value and cytological differentiation. J. Urol., 144: 1408, 1990.
19. Lerner, S. E., Blute, M. L., Eickholt, J. T. and Bergstralh, E. J.: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J. Urol., part 2, 153: 390A, abstract 648, 1995.
20. Cheng, W. S., Frydenberg, M., Bergstralh, E. J., Larson-Keller, J. J. and Zincke, H.: Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology, 42: 283, 1993.
21. Ruckle, H., Oesterling, J. E. and Zincke, H.: Relationship of high pre-prostatectomy prostate-specific antigen (PSA) levels to postoperative PSA levels and outcome in prostate cancer (PC). J. Urol., part 2, 151: 340A, abstract 450, 1994.
22. Kleer, E., Larson-Keller, J. J., Zincke, H. and Oesterling, J. E.: Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology, 41: 207, 1993.
23. Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol., 142: 1011, 1989.
24. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. B., MacFarlane, M. T. and Southwick, P. C.: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol., 151: 1283, 1994.
25. Catalona, W. J., Smith, D. S., Ratliff, T. L. and Basler, J. W.: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J.A.M.A., 270: 948, 1993.
26. Carter, H. B., Pearson, J. D., Metter, E. J., Brant, L. J., Chan, D. W., Andres, R., Fozard, J. L. and Walsh, P. C.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J.A.M.A., 267: 2215, 1992.
27. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A. and Lieber, M. M.: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. J.A.M.A., 270: 860, 1993.
28. Lilja, H.: Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol. Clin. N. Amer., 20: 681, 1993.